United Therapeutics (UTHR) Misses Q4 EPS by 69c, Revenues Miss
Get Alerts UTHR Hot Sheet
Revenue Growth %: +22.3%
Financial Fact:
Research and development: 45.9M
Today's EPS Names:
UXIN, TOWN, NRIM, More
Join SI Premium – FREE
United Therapeutics (NASDAQ: UTHR) reported Q4 EPS of $1.96, $0.69 worse than the analyst estimate of $2.65. Revenue for the quarter came in at $311.1 million versus the consensus estimate of $357.77 million.
"Following the positive results of the INCREASE study of Tyvaso® (treprostinil) Inhalation Solution in pulmonary hypertension associated with interstitial lung disease (ILD), we're looking forward to submitting a supplemental new drug application to expand the Tyvaso label mid-year that, if approved, could expand Tyvaso's addressable U.S. population by more than 30,000 patients and help patients with no available approved therapies control their pulmonary hypertension associated with ILD," said Martine Rothblatt, Ph.D., Chairman and Chief Executive Officer of United Therapeutics. "After INCREASE, we're looking forward to continued progress on three new infusion systems for delivery of parenteral treprostinil over the next 18 months: the launch of the Remunity™ system by July of this year, FDA action on the Trevyent® system, and the potential launch of the Implantable System for Remodulin expected next year."
Michael Benkowitz, President and Chief Operating Officer of United Therapeutics, commented, "Overall, we are pleased with the growth in our treprostinil products in 2019, and in particular, the strength in Remodulin new patient starts and active patients on therapy, despite generic competition for most of the year. With 2020 representing the first full year of an expanded Orenitram® label reflecting the FREEDOM-EV results, and the anticipated near-term launch of Remunity, we're confident in our ability to grow our net revenue over 2019 levels."
For earnings history and earnings-related data on United Therapeutics (UTHR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- Michelin misses Q1 sales estimates amid weaker volumes
- CBIZ, Inc. (CBZ) Tops Q1 EPS by 5c; offers guidance
Create E-mail Alert Related Categories
Corporate News, Earnings, Management CommentsRelated Entities
Earnings, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!